Contact us Demo our platform

Metabolon @

ELRIG Drug Discovery 2025

Join Metabolon at ELRIG Drug Discovery 2025 

Metabolon is proud to attend ELRIG Drug Discovery 2025 from 21 to 22 October 2025 at Liverpool, UK. This event unites over 3,000 delegates — scientists, technologists, life-science companies, academic investigators, and R&D leaders — in Europe’s leading festival of drug discovery and life sciences.  

You will find Elisabeth Stork and Simoné de Faria Maraschin in the poster area.

Come by to learn more about how metabolomics accelerates biomarker discovery, deepens mechanistic understanding, and bridges translational gaps in drug development pipelines. 

Key themes at ELRIG Drug Discovery 2025 

  • Translating ideas into therapies 
  • Chemical biology & small molecule innovation 
  • Omics & multi-omics integration 
  • Advanced disease models & high-content screening 
  • AI, machine learning, and computational biology 
  • Robotics, automation, assay miniaturization 
  • Oncology, neurodegeneration, and target validation 

Metabolon plays a key role in advancing drug discovery and translational medicine by providing a real-time view of the biochemical activities occurring within the body. 

The Role of Metabolomics in ELRIG Drug Discovery 2025 

Unlike genomics or proteomics, which only infer potential function, metabolomics captures the end products of cellular processes, offering real-time insight into physiological states, disease progression, and therapeutic response. 

Uniquely, metabolomics sits at the intersection of genetics, lifestyle, the environment, and the effect of the microbiome, reflecting the cumulative impact of these factors on an individual’s health. It bridges the gap between genotype and phenotype, accelerating translational research and making precision medicine more predictive, preventive, and effective. 

Find out more: 

Learn more about Metabolon by visiting our poster: 

  • “Advancing Drug Discovery through Metabolomics-Driven Multiomics Integration” 

Why visiting Metabolon’s booth at ELRIG Drug Discovery 2025 

With 25 years of scientific expertise, over 4,000 publications, more than 15,000 completed projects, and the world’s largest curated metabolite reference library (with more than 5,400 level 1 and level 2 annotated metabolites), Metabolon is the global leader in metabolomics. 

Our platform is built on high-resolution mass spectrometry, rigorous quality controls, and a deep biochemical understanding that ensures accurate identification and quantification of metabolites across diverse sample types. 

To maximize the value of metabolomic data, Metabolon offers an Integrated Bioinformatics Platform that empowers researchers to combine other omics datasets (such as genomics, transcriptomics, and proteomics) in a single, unified environment. Designed for collaboration and with advanced statistical tools, interactive visualizations, machine learning capabilities, the platform enables research teams across disciplines to jointly explore data, annotate findings, and generate hypotheses in real time. 

Don’t stay behind – incorporate high-quality metabolomics analysis in your project. Book a meeting with our team using the form on this page to discover how our biology-first approach reveals novel, clinically actionable biomarkers that drive precision medicine forward. 

Meet Metabolon’s Team at ELRIG Drug Discovery 2025 

  • Lisa Storck, Business Development Executive 
    As Business Development Executive for South UK, Lisa supports commercial and academic clients advance their research through Metabolon’s world-leading metabolomics solutions. Lisa holds a PhD in Chemical Biology from Imperial College London and brings 12 years of expertise in LC-MS-based analysis of biomolecules. Her passion is combing collaboration and scientific integrity with a consultative approach, to empower clients to translate research into maximum impact. Lisa is based in London. 
  • Simoné de Faria Maraschin, Director International Sales. 
    Simoné currently leads the International Sales Team at Metabolon, supporting Metabolon’s customers throughout EMEA and APAC regions. She holds a PhD in Molecular and Cell Biology by Leiden University, The Netherlands. She has worked for more than 15 years for the Agrifood and Lifesciences industry, where she led different research departments. After her MBA in 2016, she has been fully dedicated to providing pre-clinical and clinical research solutions to academic and industrial customers. She is passionate about product innovation and client satisfaction. Simone is based in Tours, France. 

Learn more about the event: 

https://elrig.org/portfolio/drug-discovery-2025/ 
Dates: 21–22 October 2025 
Location: ACC Liverpool, Liverpool, UK 

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.